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cense.Abstract Introduction: Interest in B-cells has been revived due to the description of new functions.
Supporting a role for B-cells in the genesis of autoimmune diseases is the fact that the B-cell-
activating factor of the TNF ligand family (BAFF) is essential in their physiology. The role of
BAFF, a new cytokine, in autoimmune diseases has been highlighted.
Aim of the work: To assess serum BAFF level in systemic sclerosis (SSc) and systemic lupus erythe-
matosus (SLE) to verify its role in these diseases and ﬁnd any relation with the clinical manifesta-
tions, laboratory investigations, disease activity and damage.
Patients and methods: The study included 12 SSc and 40 SLE patients. The patients were subjected
to full history taking and thorough clinical rheumatological and dermatological examinations and
relevant investigations including autoantibodies and CT chest in SSc. In SSc, the total skin thick-
ness score was scored according to the modiﬁed Rodnan skin score (MRSS) method. In SLE, the
disease activity was assessed using the Systemic Lupus Activity Measure (SLAM) and organ567975; fax: +20 225085372.
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46 S.M. Fawzy et al.damage using the Systemic Lupus International Collaborating Clinics/ACR (SLICC/ACR) index.
The serum BAFF levels were measured using a speciﬁc ELISA.
Results: The BAFF level was remarkably elevated in SSc and SLE in a comparable percentage of
patients, yet the level was highest in SLE and lower in the limited SSc subtype. The BAFF signif-
icantly correlated with the level with the MRSS in SSc and with both the SLAM and SLICC in SLE
patients.
Conclusion: The elevated level of BAFF in SSc further conﬁrms the importance for new therapeutic
targets for its inhibition to slow the disease progression, particularly skin ﬁbrosis. The role of BAFF
in the pathogenesis and disease activity in SLE is well-known and the novel noticeable correlation
with the damage index high lightens on the utility of BAFF as an indicator of disease damage and
predictor of poor outcome.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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It is increasingly recognized that B cells have multiple func-
tions that contribute to the pathogenesis of autoimmunity.
They produce autoantibodies that mediate tissue injury, they
function as antigen-presenting cells that present epitopes of self
antigens to autoreactive T cells, and they produce soluble
mediators involved in the organization of lymphoid tissue
and in the initiation and perpetuation of inﬂammatory pro-
cesses [1]. In some autoimmune diseases, B cells migrate to in-
ﬂamed sites, where they act as local effector cells [2].
B-cell-activating factor belonging to the tumor necrosis fac-
tor family (BAFF), or B cell-activating factor, also known as B
lymphocyte stimulator (BLyS) is a member of the tumor
necrosis factor (TNF) superfamily and is best known for its
role in the survival and maturation of B cells [3]. BAFF is pro-
duced by monocytes, macrophages, neutrophils, dendritic cells
and T lymphocytes [4] and is a ligand for several receptors
including B cell maturation antigen (BCMA) and BAFF recep-
tor (BAFF-R) [5,6] which are primarily expressed by B cells
[3]. It has been postulated that BAFF may play a pathogenic
role in autoimmune diseases through stimulation of T-cell
dependant B cell autoantibody production [7]. B cells contrib-
ute to the enhanced levels of circulating BAFF. The aberrant
up-regulation of this cytokine may initiate a vicious circle in
which enhanced levels of BAFF act in an autocrine manner
to reinforce the systemic activation of the humoral immune
system [8].
Systemic autoimmune diseases are characterized by a com-
plex aetiology with multiple pathogenic factors. Disturbed B-
cell biology and humoral immunity including B-cell-activating
factor (BAFF)-mediated processes have been described. Dys-
regulated BAFF expression may lead to disease progression
and perpetuation of humoral autoimmunity and was proposed
to contribute to the development of B-cell malignancies [9].
Systemic lupus erythematosus (SLE) is a chronic, usually
life long, potentially fatal autoimmune disease characterizes
by increased production of autoantibodies, impairment of B-
and T-cell functions, cytokine production, and immune com-
plex deposition [10]. Overexpression of BAFF is considered
to be a characteristic feature of systemic autoimmune diseases
particularly SLE [11]. Expression of BAFF in the sera of SLE
patients detected signiﬁcantly elevated levels of BAFF in SLE
patients when compared with controls [12,13]. Further studies
followed and detected elevated BAFF levels in SLE patients
and conﬁrmed its crucial role in the development and progres-sion of SLE as a well-known representative of systemic auto-
immune diseases [14,15].
Systemic sclerosis (SSc) is a connective tissue disease char-
acterized by autoimmunity and tissue ﬁbrosis. In patients
with SSc, there is a close association between the presence
of speciﬁc autoantibodies and the development of clinical fea-
tures. Although it is known that cytokines, including trans-
forming growth factor-beta, can modulate the synthesis of
extracellular matrix by ﬁbroblasts, it is not clear how autoim-
munity and tissue ﬁbrosis are interrelated. Several recent lines
of evidence indicate a potential role for B cells [16]. Recent
preclinical and clinical studies lend support to the notion that
B-cell depletion is a promising therapeutic target in patients
with systemic sclerosis. Evidence is provided by the marked
effects of rituximab treatment on skin thickening, functional
ability, and disease activity in conjunction with effects on
lesional and circulating B cells and BAFF [17]. It is noticeable
that BAFF and its signaling in B cells contribute to B cell
abnormalities and disease development in patients with SSc
[18].
The association of each of these diseases with autoantibody
production suggests a potential role of BAFF in the disease
process.2. Aim of the work
The aim of the present study was to estimate the serum BAFF
level in systemic sclerosis and compare it to that of SLE pa-
tients; trying to verify its role in these diseases and to ﬁnd
any relation with the clinical manifestations, laboratory inves-
tigations, disease activity and damage.3. Patients and methods
The study included 12 SSc and 40 SLE patients recruited from
the Rheumatology and Dermatology departments and outpa-
tient clinics, Faculty of Medicine, Cairo University hospitals.
The mean age of the SSc patients was 43.75 ± 14 years (range:
22–65 years) while the mean age of the SLE patients was
29.2 ± 8.5 years (range: 17–52 years). Twelve age and sex
matched healthy individuals served as controls.
All patients fulﬁlled the American College of Rheumatol-
ogy criteria for PSS [19] and were considered as limited or dif-
fuse according to the classiﬁcation system proposed by Le Roy
et al. (1988) [20]. Systemic lupus erythematosus patients were
Table 1 Clinical manifestations and laboratory investigations
of the systemic sclerosis patients.
Parameter Systemic sclerosis
patients (12)
Clinical manifestation, No. (%)
Raynauds phenomenon 12 (100)
Sclerodactyl 10 (83.3)
Constitutional 5 (41.7)
Digital ulceration and pitting scars 9 (75)
Dysphagia 9 (75)
Dyspnea 9 (75)
Hemoptysis 0 (0)
Cough (parenchymal involvement) 6 (50)
Chest pain 0 (0)
Neurological 3 (25)
Myalgia/muscle weakness 4 (33.33)
Renal 0 (0)
Arthralgia 4 (33.33)
Arthritis 0 (0)
Laboratory investigations (mean ± SD)
MCV 80.58 ± 7.79
WBC (thousands/mm3) 8.29 ± 2.18
Platelets (thousands/mm3) 234.92 ± 49.47
ESR (mmHg/1st hour) 41.75 ± 28.47
ALT (U/l) 27.83 ± 15.24
AST (U/l) 22.33 ± 7.97
Urea (mg/dl) 21.25 ± 5.07
Creatinine (mg/dl) 0.72 ± 0.14
ANA, No. (%) 10 (95)
Anti-dsDNA, No. (%) 5 (82.5)
Anti-ScL 70, No. (%) 3 (25)
Anti-centromere, No. (%) 9 (75)
Modiﬁed Rodnan severity score (MRSS) 1.24 ± 0.44
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revised criteria for the SLE [21]. The patients were subjected
to full history taking and thorough clinical examination
including a detailed rheumatological and dermatological
examinations.
Dermatological examination for skin sclerosis, its extent,
Raynaud’s phenomenon, mat-like telengectasia, ﬁsh mouse,
trophic changes of the ﬁngers as digital ulcerations, scarring
and other clinical manifestations of SS were looked for. Cuta-
neous manifestations of SLE were also considered. Rheumato-
logical examination included assessment of the locomotor
system including tenderness of joints and arthritis. Total skin
thickness score was scored according to the modiﬁed Rodnan
skin score (MRSS) method [22]. In SLE the Disease activity
was assessed using the Systemic Lupus Activity Measure
(SLAM) [23] and organ damage using the Systemic Lupus
International Collaborating Clinics/ACR (SLICC/ACR) index
[24].
Routine laboratory investigations including, complete blood
count (CBC), erythrocyte sedimentation rate (ESR), liver and
kidney function tests, and complete urine analysis were per-
formed and autoantibodies including antinuclear antibodies
(ANA), anti-dsDNA, anti-ScL 70 and anti-centromere antibod-
ies was determined. Chest CT was performed for assessment of
the pulmonary parenchyma in the SSc patients.
The serum BAFF levels were measured using a speciﬁc
ELISA kit (R&D Systems, Minneapolis, MN) according to
the manufacturer’s protocol. The detection limit of this assay
was 0.00338 ng/ml. This assay employs the quantitative sand-
wich enzyme immunoassay technique. A monoclonal antibody
speciﬁc for BAFF has been pre-coated onto a microplate.
Standards and samples are pipetted into the wells and any
BAFF present is bound by the immobilized antibody. After
washing away any unbound substances, an enzyme-linked
polyclonal antibody speciﬁc for BAFF is added to the wells.
Following a wash to remove any unbound antibody-enzyme
reagent, a substrate solution is added to the wells and color
develops in proportion to the amount of BAFF bound in the
initial step. The color development is stopped and the intensity
of the color is measured using ELISA reader. The concentra-
tion of the BAFF in serum samples is calculated after creation
of the standard curve.
Serum BAFF level was assessed and graded to be normal at
values <0.5 ng/ml, mildly elevated at values (0.5–1 ng/ml),
moderately elevated at values (1–2 ng/ml), and markedly ele-
vated at values more than 2 ng/ml.
3.1. Statistical analysis
Data were statistically described in terms of range, mean ±
standard deviation (SD), median, frequencies (number of
cases) and percentages when appropriate. Comparison of
quantitative variables between the study groups was done
using Mann–Whitney U-test for independent samples. For
comparing categorical data, Chi-square (v2) test was per-
formed. Exact test was used instead when the expected
frequency is less than 5. A probability value (p value) less than
0.05 was considered statistically signiﬁcant. All statistical cal-
culations were done using computer programs Microsoft Excel
2003 (Microsoft Corporation, NY, USA) and SPSS (Statistical
Package for the Social Science; SPSS Inc., Chicago, IL, USA)
version 15 for Microsoft Windows.4. Results
The study included 52 patients: 12 SSs patients and 40 SLE
patients. The SSc patients included 11 females (91.67%) and a
male (8.3%), their ages ranged from 22 to 65 with a mean of
43.75 ± 14 years. Disease duration ranged from 3 to 20 years
with a mean of 10.33 ± 5.76 years. The SS patients included
10 (83.3%) with acrosclerosis (limited) and 2 (16.7%) with dif-
fuse systemic sclerosis. None of the SSc patients was receiving
corticosteroids or any other Disease modifying Antirheumatic
drug (DMARD). They were only receiving symptomatic treat-
ment. The clinical manifestations, laboratory investigations
and modiﬁed Rodnan skin score (MRSS) are presented in
Table 1.
All the SLE patients were females, their ages ranged from
17 to 52 with a mean of 29.2 ± 8.5 years. Disease duration
ranged from 1 to 19 years with a mean of 7.18 ± 4.55 years
and 23 were married. All the studied SLE patients were receiv-
ing a low dose of corticosteroids and hydroxychloroquine. The
clinical manifestations and laboratory investigations of SLE
patients are presented in Table 2.
The study also included 12 healthy subjects, they were all
females their ages ranging from 20 to 54 years with a mean
of 30.12 ± 8 years. The mean serum level of BAFF in the con-
trols was 0.517 ± 0.18 ng/ml. The level was normal in 9 sub-
jects (75%) and only mildly elevated in 3 persons (25%).
Table 2 Clinical manifestations and laboratory investigations
of the systemic lupus erythematosus patients.
Parameter SLE patients (12)
Clinical manifestation, No. (%)
Weight loss 13 (32.5)
Fatigue 14 (35)
Fever 22 (55)
Photosensitivity 35 (87.5)
Malar rash 31 (77.5)
Discoid rash 3 (7.5)
Arthralgia/arthritis 34 (85)
Arthritis 20 (50)
Myalgia/muscle weakness 13 (32.5)
Pleurisy 34 (85)
Nephritis 24 (60)
Laboratory investigations (mean ± SD)
Hb (g/dl) 10.57 ± 1.76
WBC (thousands/mm3) 11.64 ± 31.03
Platelets (thousands/mm3) 248.08 ± 125.1
ESR (mmHg/1st hour) 49 ± 29.15
24 hr urine protein 0.99 ± 1.15
Disease activity and damage
SLAM 19.35 ± 12.25
SLICC 5.65 ± 2.56
Figure 2 Correlation of the BAFF level (ng/ml) and the
modiﬁed Rodnan skin thickness score in systemic sclerosis
patients.
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being normal in 9 (75%) and renal function tests were normal
in all the SSc patients. The Chest CT showed altered pulmon-
ary parenchyma in 6 (50%) of the SSc patients with four hav-
ing ground glass appearance and two with a honey comb
picture.
In SSc the mean BAFF level was 1.06 ± 0.29 ng/ml (range
0.48–1.56 ng/ml) and was signiﬁcantly higher when compared
to the control subjects (p< 0.01), however, the level was still less
than the elevation in the SLE patients (Fig. 1). Serum BAFF
level was elevated in 8 patients (66.6%), 3 patients (25%) of high
elevation, 4 patients (33.3%) of moderate elevation, and one
patient (8.3%) of mild elevation. The level was normal in 4
SSc patients. The mean level of BAFF was obviously higher in
the two diffuse SSc patients (1.41 ± 0.21 ng/ml) compared to
the limited SSc form (0.98 ± 0.25 ng/ml).Figure 1 BAFF level (ng/ml) in SSc and SLE patients and the
control. H= Signiﬁcantly different from the BAFF level in SSc
and SLE patients.In SSc patients there was a signiﬁcant correlation of the
BAFF level with the MRSS (r= 0.77, p = 0.003) (Fig. 2)
and a negative one with the age of the patients (r= 0.8,
p = 0.002). There was no signiﬁcant correlation with any of
the clinical manifestations or laboratory investigations.
In SLE the mean serum level of the BAFF was
1.47 ± 1.54 ng/ml (range 0.05–6.3 ng/ml). Serum BAFF level
was elevated in 26 patients (65%): markedly elevated in 10 pa-
tients (25%), moderately elevated in 12 (30%), mildly elevated
in 4 (10%) and normal in 14 patients (35%) which was statis-
tical signiﬁcantly higher in comparison with the controls
(p= 0.001).
The serum BAFF level of SLE was higher than that of the
SSc patients however; the difference did not reach signiﬁcance
(p= 0.11). On comparing the level in SLE with that in the lim-
ited SSc subtype, the difference became greater (p= 0.06).
Fig. 1 shows the level of BAFF in the SSc and SLE patients
compared to the control.
In SLE patients, there was a signiﬁcant correlation between
the BAFF level and the diseases activity (SLAM) and damage
(SLICC) (r= 0.88, p = 0.000 and r= 0.66, p= 0.000, respec-
tively) (Fig. 3). There was a tendency of the BAFF level to in-
crease with an increase in the disease duration (r= 0.3,
p = 0.07) and with thrombocytopenia (r= 0.3, p = 0.06).Figure 3 Correlation of the BAFF level (ng/ml) with the disease
activity (SLAM) and damage (SLICC) indices in SLE patients.
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Interest in B-cells has been revived due to the description of
new functions. Supporting a role for B-cells in the genesis of
autoimmune diseases is the fact that the B-cell-activating fac-
tor of the TNF ligand family (BAFF) is essential in their phys-
iology. The role of BAFF, a new cytokine, in autoimmune
diseases has been highlighted. Excessive production of BAFF,
alters immune tolerance by rescuing self-binding B-cells. Over-
expression leads to autoimmune manifestation, and BAFF lev-
els are elevated in the serum of patients with autoimmune
diseases [25].
In the present study, serum BAFF level was elevated in SSc
patients and signiﬁcantly higher than that of the controls.
While the elevation was present in a comparable percentage
of SSc (66.66%) and SLE (65%) patients, yet the level was
higher in SLE. Serum levels of BAFF, a potent B-cell survival
factor, are elevated in patients with systemic autoimmune dis-
eases, such as SLE, rheumatoid arthritis and SSc [15].
In the present study the elevated BAFF level was present in
the SSc patients who were mostly of the limited type. Further-
more, the BAFF level signiﬁcantly correlated with the total
skin thickness score assessed according to the modiﬁed Rod-
nan total skin thickness scores (MRSS). This is in agreement
with limited studies showing similar results in systemic sclero-
sis. Systemic sclerosis patients with elevated BAFF levels had
signiﬁcantly higher MRSS compared with patients with nor-
mal BAFF levels. BAFF levels correlated positively with
MRSS in SSc patients [26]. The BAFF levels in localized
scleroderma were elevated and comparable with those of SSc
or SLE. Moreover, serum BAFF levels correlated positively
with the severity of skin lesion as well as the number of skin
lesions. These ﬁndings make the suggested contribution of
BAFF to autoimmunity and disease development in sclero-
derma, more likely accepted [15]. The serum level of BAFF
is elevated in SSc patients compared to control and related
to its clinical features. A signiﬁcant positive correlation was
found with the extent of skin ﬁbrosis [18]. Chronic B cell acti-
vation is critical not only for induction of autoantibodies but
also for the development of skin sclerosis [27]. Although the
pathogenesis of SSc remains unknown, B cell abnormalities
characterized by autoantibody production and polyclonal B
cell activation play an important role [26].
In a related study on serum BAFF in SSc, the results were
comparable as the level was signiﬁcantly higher in patients
(median 1.26 ng/ml; range 0.32–5.67) compared to the level
in healthy controls (median 0.78 ng/ml; range 0.39–1.37).
Moreover, serum BAFF levels were even signiﬁcantly higher
in SLE patients (median 1.63 ng/ml; range 0.56–5.52) com-
pared to the level in healthy controls. In agreement to the cur-
rent results, SLE patients had the highest median serum BAFF
levels. Concerning SSc subtypes, BAFF levels were elevated in
both patients with diffuse subtype (median 1.30 ng/ml) and
those with limited (median 1.16 ng/ml). Furthermore, serum
BAFF levels were signiﬁcantly elevated in patients with diffuse
relative to those with limited SSc [26].
Studies in SSc are difﬁcult and complex resulting from its
low incidence, heterogeneity in clinical presentations, and nat-
ural disease course. With a potentially effective and relatively
safe drug in hand, however, the time has come to try to break
the deadlock in SSc treatment [17]. It is suggested that BAFFand its signaling in B cells contribute to B cell abnormalities
and disease development in SSc [26]. Comprehensive biomark-
ers as BAFF should be part of clinical studies to understand
how anti-B cell target therapies affects the different pathoge-
netic pathways implicated in SSc [17].
Similar to the existing ﬁndings, BAFF levels were elevated
in 52% of SSc patients being higher in diffuse SSc than the lim-
ited subtypes [26]. In the present results, there was a tendency
of the BAFF level to increase with an increase in the disease
duration in SSc. The BAFF levels did not correlate with dis-
ease duration in patients with SSc [26].
Several studies reported the elevated serum BAFF levels in
patients with SLE [12–14]. The results of our study could not
ﬁnd a signiﬁcant relationship between elevated BAFF level and
positive expression of either ANA or anti-dsDNA antibodies.
In accordance to this ﬁnding, were the results of elevated
BAFF in SLE patients that were not able to ﬁnd a relationship
with anti-dsDNA antibodies [28].
The present SLE patients were receiving a low dose of cor-
ticosteroids which were ineffective in normalizing the serum
BAFF level. SLE patients receiving a high dose of corticoste-
roids had a marked reduction in serum BAFF level down to
its normal range and tapering resulted in a rebound increase
[14].
In the present study, the BAFF level signiﬁcantly correlated
with the disease activity (SLAM) and damage (SLICC) indices.
Similarly, BAFF levels correlated positively with SLEDAI act
as biomarkers for active disease in SLE patients [8,28,29]. In
another study, the modulation of BAFF-R expression in SSc
and SLE was related to disease activity. In SLE patients with
more active disease, the BAFF-R level on B cells was lower
than in patients with lower disease activity. As the serum
BAFF level is usually increased in pSS and SLE, there is an
associated decreased expression of BAFF-R on peripheral
lymphocytes [30]. Both BAFF and BAFF-R were suggested
markers of disease activity in SLE.
Systemic lupus erythematosus (SLE) is a complex immune
disorder in which pathogenic autoantibodies damage target or-
gans including the skin, joints, brain, and kidney. B cells are
essential to lupus pathogenesis, not only because they produce
the pathogenic autoantibodies but also because they have mul-
tiple effector functions in the immune system. There has been
increasing interest in targeting of B cells for the treatment of
SLE and other autoimmune diseases. BAFF is a crucial
homeostatic cytokine for B cells that is upregulated during
inﬂammation and excessive levels may contribute to perpetua-
tion of SLE [31]. To our knowledge, this is the ﬁrst study to
correlate the BAFF level with the damage index in SLE and
highlight its important contribution not only as a marker of
disease activity but as a predictor of damage.
The use of B-cell targeted therapies for the treatment of
SLE has generated great interest owing to the multiple patho-
genic roles carried out by B cells in this disease. Strong support
for targeting B cells is provided by genetic, immunological and
clinical observations that place these cells at the center of SLE
pathogenesis, as initiating, amplifying and effector cells. Inter-
est in targeting B cells has also been fostered by the successful
use of similar interventions to treat other autoimmune diseases
such as rheumatoid arthritis, and by the initial promise shown
by B-cell depletion to treat SLE in early studies. Using agents
that inhibit BAFF have renewed vigor instilled in the ﬁeld of
50 S.M. Fawzy et al.B-cell depletion and identiﬁed several new avenues for the ther-
apeutic targeting of B cells in SLE [32].
Advances in our understanding of the BAFF system offer
the opportunity to improve our therapeutic approach [25].
BAFF has been shown to be a therapeutic target in SLE, how-
ever, as few basic therapies for skin sclerosis and lung ﬁbrosis
in SSc were established, new therapeutic agents are arising [33].
Inhibition of BAFF represented a successful treatment in a
murine model of SLE [6,34]. Moreover, treatment with BAFF
antagonists, such as human anti-BAFF mAb, was promising
and showed safety [35,36]. Elevated serum BAFF levels were
associated with increased disease severity and activity in SSc
suggesting that BAFF inhibition could be a potential thera-
peutic target in SSc as well as SLE [26].
In conclusion, the elevated level of BAFF in SSc further
conﬁrms the importance for new therapeutic targets for its inhi-
bition to slow the disease progression, particularly skin ﬁbrosis.
The role of BAFF in the pathogenesis and disease activity in
SLE is well-known and the novel noticeable correlation with
the damage index high lightens on the utility of BAFF as an
indicator of disease damage and predictor of poor outcome.References
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